Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A compound of formula (I):



(I)

wherein

A and E are each carbon;

one of B and D is carbon, and one of B and D is nitrogen;

~~A, B, D and E are each C or N with the proviso that one or more are N;~~

R^1 and R^2 are each independently hydrogen, halogen, hydroxy, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, haloC_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkoxy, hydroxyC_{1-6}alkoxy, C_{3-7}cycloalkyl, C_{3-5}cycloalkylC_{1-4}alkyl, NR^7R^8, carboxy, esterified carboxy, C_{1-6}alkyl substituted with a group selected from NR^7R^8, carboxy and esterified carboxy, or C_{1-6}alkoxy substituted with a group selected from NR^7R^8, carboxy and esterified carboxy;

R^3 and R^4 are each independently hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl;

R^5 and R^6 are, at each occurrence, independently hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}acyloxy, carboxy, esterified carboxy, $CONR^7R^8$, SO_2R^7, $SO_2NR^7R^8$, aryl, heteroaryl, heterocyclyl, or C_{1-6}alkyl substituted with a group selected from hydroxy, C_{1-6}alkoxy, C_{1-6}acyloxy, carboxy, esterified carboxy, NR^7R^8, $CONR^7R^8$, SR^7, SO_2R^7, $SO_2NR^7R^8$, aryl, heteroaryl and heterocyclyl; or R^5 and R^6 and the carbon atom to which they are attached together form a carbocyclic ring of 3 to 6 carbon atoms;

R^7 and R^8 are, at each occurrence, independently hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-7}cycloalkyl or fluoroC_{1-6}alkyl;

or R^7 and R^8 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C_{1-4}alkoxy, which

ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, a group S(O) or $S(O)_2$, or a second nitrogen atom which will be part of a NH or NR^a moiety where R^a is C_{1-4}alkyl optionally substituted by hydroxy or C_{1-4}alkoxy;

X is an oxygen ~~or sulfur atom or the group =NCN~~;

Y is an aryl group selected from unsubstituted naphthyl and phenyl or naphthyl substituted by one or two substituents selected from halogen, C_{1-4}alkyl, C_{1-4}alkoxy, haloC_{1-4}alkyl, haloC_{1-4}alkoxy, phenyl, cyano, nitro, pyrazolyl, di(C_{1-6}alkyl)amino, phenoxy, $-OCH_2O-$ and C_{1-6}alkylcarbonyl; or Y is a heteroaryl group selected from pyridyl, thiazolyl, isoxazolyl, oxadiazolyl and pyrazolyl wherein each heteroaryl group is optionally substituted with one or two substituents selected from C_{1-4}alkyl, C_{1-4}alkoxy, haloC_{1-4}alkyl, haloC_{1-4}alkoxy, unsubstituted heteroaryl or phenyl which may be substituted by C_{1-6}alkyl or halogen; or Y is a fused-carbocyclyl group which is a C_{5-7}cycloalkyl radical that is fused to a phenyl ring;

~~Y is an aryl, heteroaryl, carbocyclyl or fused carbocyclyl group; and~~

n is zero ~~either zero or an integer from 1 to 3~~;

or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof.

2. (previously presented) A compound according to claim 1 in which X is O.

3. (previously presented) A compound according to claim 1 in which R^3 and R^4 are hydrogen.

4. (previously presented) A compound according to claim 1 in which B is nitrogen and A, D and E are carbon.

5. (canceled)

6. (previously presented) A compound according to claim 1 wherein R^5 and R^6 each independently represent a hydrogen atom or a C_{1-4}alkyl or phenyl group.

7. (previously presented) A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt or N-oxide thereof.

8. (previously presented) A compound according to claim 1 or a pharmaceutically acceptable salt or N-oxide thereof for use in a method of treatment of the human or animal body by therapy.

9. (canceled)

10. (currently amended) ~~A method of treating a subject suffering from a disease or condition in which pain and/or inflammation predominates which comprises administering to that subject a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt or N-oxide thereof.~~ A method for treating pain, which method comprises administering to a mammalian patient in need thereof a therapeutically effective amount of the compound of Claim 1.

11. (canceled)

12. (new) The compound N-Isoquinolin-5-yl-N'-[4-(trifluoromethyl)phenyl]urea, or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof.

13. (new) The compound of claim 1, wherein Y is an aryl group selected from unsubstituted naphthyl and phenyl or naphthyl substituted by one or two substituents selected from halogen, C_{1-4}alkyl, C_{1-4}alkoxy, haloC_{1-4}alkyl, haloC_{1-4}alkoxy, phenyl, cyano, nitro, pyrazolyl, di(C_{1-6}alkyl)amino, phenoxy, -OCH_2O- and C_{1-6}alkylcarbonyl.

14. (new) The compound of claim 1, wherein Y is a heteroaryl group selected from pyridyl, thiazolyl, isoxazolyl, oxadiazolyl and pyrazolyl wherein each heteroaryl group is optionally substituted with one or two substituents selected from C_{1-4}alkyl, C_{1-4}alkoxy, haloC_{1-4}alkyl, haloC_{1-4}alkoxy, unsubstituted heteroaryl or phenyl which may be substituted by C_{1-6}alkyl or halogen.

15. (new) The compound of claim 1, wherein Y is a fused-carbocyclyl group which is a C_{5-7}cycloalkyl radical that is fused to a phenyl ring.